DocketNumber: Case No. 1:17 CV 411
Judges: Gaughan
Filed Date: 2/1/2019
Status: Precedential
Modified Date: 10/18/2024
INTRODUCTION
This matter is before the Court upon Accordant Energy, LLC's Motion to Dismiss Defendants' Counterclaims for Lack of Subject Matter Jurisdiction (Doc. 109). This is a patent case. For the reasons that follow, the Motion is GRANTED in PART and DENIED in PART. The Counterclaims are DISMISSED, but the Court retains jurisdiction to entertain a motion pursuant to
FACTS
Only those facts relevant to a resolution of the instant motion are set forth herein. Plaintiff Accordant Energy, LLC brings this lawsuit against defendants Vexor Technology, Inc. and Vexor Technology, LLC
[Plaintiff], solely on behalf of itself and any successors-in-interest to the '268 Patent and/or the '051 Patent, hereby unconditionally covenants not to file or maintain any lawsuit anywhere in the world against defendant for the infringement or alleged infringement of the [patents] for any past, present, or future manufacture, sale, offer for sale, or importation by [defendant] of the waste-driven fuel currently marketed as Vexor Engineered Fuel®. [Plaintiff] further covenants not to file or maintain any lawsuit anywhere in the world for the infringement or alleged infringement of the [patents] by customers of [defendant], based on the customers' purchase or use of the waste-derived fuel currently marketed as Vexor Engineered Fuel® and that is manufactured and sold by defendant. This Covenant shall not bind or otherwise apply to any current licensees of the [patents] or to any other third parties....
Plaintiff argues that in light of the Covenant and plaintiff's dismissal with prejudice of its infringement claims, jurisdiction over defendant's counterclaims is lacking. Defendant opposes the motion.
ANALYSIS
Subject matter jurisdiction in a declaratory judgment suit requires a "substantial controversy, between the parties having adverse legal interests, of sufficient immediacy and reality to warrant the issuance of a declaratory judgment." Dow Jones & Co., Inc. v. Ablaise Ltd. ,
Prior to the Supreme Court's issuance of MedImmune , the Federal Circuit applied a "reasonable apprehension of imminent suit" test to determine whether an actual controversy exists. MedImmune rejected this approach in favor of a "totality of the circumstances" test, which is used to evaluate whether a controversy is "of sufficient immediacy and reality to warrant the issuance of a declaratory judgment." MedImmune ,
A covenant not to sue coupled with the dismissal with prejudice of pending infringement claims is one piece of "further information" that may divest a court of jurisdiction over declaratory judgment claims. Whether a covenant not to sue rises to this level "depends on what is covered by the covenant." Revolution Eyewear, Inc. v. Aspex Eyewear, Inc.,
Here, plaintiff argues that, although the Court undoubtedly had jurisdiction over the counterclaims as initially filed, the dismissal of its infringement claims and the covenant not to sue render jurisdiction lacking because there is *783no sufficient "immediacy and reality" to warrant the issuance of a declaratory judgment. In response, defendant argues that the Covenant does not eliminate subject matter jurisdiction. According to defendant: the Covenant is vague and ambiguous; the Covenant does not prohibit plaintiff from bringing suit for indirect infringement; the Covenant is impermissibly narrow because it does not cover defendant's ongoing business operations; the Covenant allows plaintiff to sue for infringement by proxy; the Covenant does not prevent plaintiff from interfering with defendant's customers; and the Covenant does not moot defendant's inequitable conduct claim in any event.
Upon review, the Court finds that defendant does not meet its burden of establishing that jurisdiction exists over its claims for declaratory relief.
The Court rejects defendant's argument that the Covenant is impermissibly vague due to the nature of the fuel at issue. Defendant claims that the cases plaintiff relies on involve "static" products that do not change in the course of the manufacturing process. On the other hand, the fuel at issue here is made in batches and the waste streams change with each batch depending on the incoming waste received. In addition, defendant claims that the parties dispute what the product "currently marketed" by defendant actually is. According to defendant, even slight changes to the waste streams or equipment used could render the fuel "different" from the product "currently" marketed. As such, the Covenant does not truly provide any protection from an infringement suit by plaintiff. The Court disagrees with defendant's position. Here, the Covenant broadly protects against an infringement suit with respect to the product "currently marketed as Vexor Engineered Fuel®." The Covenant protects defendant from an infringement suit with respect to the manner and end product currently manufactured by defendant, which was the subject of the infringement claim. The Covenant provides that defendant will not bring an infringement action against defendant for past or future sales of this product. Moreover, in its reply brief, defendant indicates that the covenant language is a "broad, complete, and accurate description of the accused product in this litigation, and it encompasses the variability that is present in this product as currently sold..." Given defendant's representation, the product at issue is no different than the "static" products for which similar covenants have been held to defeat federal jurisdiction. See, e.g., Super Sack v. Chase Packaging Corp.
To the extent that defendant alters its product in the future, the Court looks to *784the conduct of the party seeking declaratory relief, with an eye to whether the party intends to engage in potentially infringing activity, in order to determine whether an actual controversy exists. See, Cat Tech LLC v. TubeMaster, Inc. ,
Defendant further claims that a case or controversy exists because the Covenant does not prohibit plaintiff from bringing suit for indirect infringement. Plaintiff responds that the Covenant applies to the "sale" of Vexor Engineered Fuel and that any possible claims of indirect infringement would necessarily flow from any such sale. Thus, according to plaintiff, the Covenant does in fact prevent it from bringing suit for indirect infringement. Regardless, in an effort to "remove any possible ambiguity," plaintiff further confirms that the Covenant applies to both direct and indirect infringement. As a result of the "clarification," the Covenant does in fact prevent plaintiff from asserting claims not only for direct infringement, but for indirect infringement as well.
Defendant next argues that jurisdiction exists because the Covenant is impermissibly narrow in that it does not cover defendant's ongoing business operations. Defendant argues that the nature of its business requires setting up related entities at a customer location. Defendant points out that any new entity would not be covered by the Covenant. According to defendant, it has "concrete" plans to expand to new locations. Defendant currently is "in discussions" with parties regarding expansion into three areas and has a "letter of intent" for one location. Defendant is in the process of assessing that market, finding a location, and evaluating local regulations. Defendant notes that it typically forms new entities when entering a new market and those entities obtain licenses from defendant for manufacturing purposes. Yet, the Covenant does not provide protection from suit to defendant's affiliates.
Upon review, the Court rejects defendant's argument as the "immediacy" requirement is not satisfied. In Cat Tech , the Federal Circuit addressed immediacy in the context of a method patent. There, the court determined that the declaratory plaintiff satisfied the immediacy requirement because plaintiff took "significant concrete steps to conduct [the relevant allegedly infringing] activity." Cat Tech ,
Defendant also argues that jurisdiction exists because the Covenant does not prevent defendant from bringing an infringement suit by proxy. Nor does the Covenant obviate jurisdiction because the Covenant does not affirmatively provide that defendant is not an infringer. According to defendant, various customers and potential customers have inquired about the lawsuit and its impact on defendant's ability to continue in the industry. Defendant claims that the only way that it will be "free and clear" of interference from plaintiff is if the Court addresses the merits of the counterclaims. The Court rejects defendant's arguments. Although defendant notes that some of the members of plaintiff's board of directors are also licensees of plaintiff's patents, there is simply no indication whatsoever that any of the licensees are under defendant's control.
Defendant argues that even if the Covenant moots some of the counterclaims, it does not moot defendant's claim for inequitable conduct. According to defendant, its inequitable conduct claim contains a request for attorney's fees. Defendant claims that courts have routinely held that a court retains jurisdiction to consider a motion for attorney's fees even after an inequitable conduct claim is dismissed.
Upon review, the Court agrees with defendant that the Covenant does not divest the Court over defendant's request for attorney's fees asserted under
Although [Bayer] originally sought a declaratory judgment that the four Bayer patents were infringed, Bayer subsequently dismissed its infringement claims under [three patents-in-suit] and filed a....covenant[ ] not to sue Monsanto...Even if filing such a covenant may divest the court of jurisdiction over a declaratory judgment action regarding these patents...under our precedent the district court retained independent jurisdiction over Monsanto's request for attorneys fees under35 U.S.C. § 285 .
In the event the Court finds that a party engaged in inequitable conduct, the district court must declare a patent unenforceable. Id . at 1243 ("this court has long held that the unenforceability of a patent follows automatically once a patent is found to have been obtained via inequitable conduct"). This is so regardless of whether the Court maintains jurisdiction over the counterclaim itself as jurisdiction undoubtedly exists over these issues as a result of defendant's request for attorney's fees pursuant to
Plaintiff asks that the Court exercise its discretion and decline to entertain a Section 285 motion. Plaintiff further asks that the Court restrict discovery. Because these issues were raised for the first time in a reply brief, the Court will not address them at this point. Plaintiff remains free to argue in its brief in opposition to any Section 285 motion that the Court should decline to hear the motion in the first instance. The Court cautions defendant that it is not inclined to re-litigate the issues that defendant raised in connection with its Rule 11 motion for attorney's fees. As noted by the Court in National Products , the court need not "allow fee litigation to be the tail that wags the dog." See, National Products, Inc. v. Gamber-Johnson,LLC ,
*787CONCLUSION
For the foregoing reasons, the motion to dismiss is GRANTED in PART and DENIED in PART. The Counterclaims are DISMISSED, but the Court retains jurisdiction to entertain a motion pursuant to
IT IS SO ORDERED.
Two other Vexor related entities were voluntarily dismissed without prejudice and are no longer parties to this lawsuit.
Super Sack and Amana Refrigeration were decided pre-MedImmune , but the Federal Circuit continues to cite these cases with approval in applying MedImmune 's jurisdictional test. See, e.g., Dow Jones,
The fact that plaintiff may have attempted to get its licensees to consent to a settlement does not mean that, absent the Covenant, plaintiff will be able to bring an infringement action through its licensees.